Volume 134, Issue 5



August 1, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Erythroblastic island macrophages characterized erythropoietin-receptor expression. See the article by Li et al.

Identification and transcriptome analysis of erythroblastic island macrophages
This study substantiates the role of the macrophage in the formation of erythroblastic islands (EBIs) and reveals that erythropoietin receptor (Epor) expression marks the central macrophage of the EBI. Treatment with Epo increases the number of EBIs and erythroblasts surrounding the central macrophage.

How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns
In this Blood Spotlight, the authors examine current treatment options for acute thrombotic thrombocytopenic purpura (TTP).

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
This article reports promising results of a new triple combination that includes carfilzomib and daratumumab for lenalidomiderefractory myeloma.

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
This unique large-population study examines the prevalence of JAK2 V617F and CALR mutations in the general population, and suggests higher rates of subclinical myeloproliferative neoplasms in the general population associated with higher blood counts and increased thrombotic risk.

Combined inhibition of Bcl-2 and NFkB synergistically induces cell death in cutaneous T-cell lymphoma
These investigations offer evidence in support of synergistic therapeutic targeting of the Bcl-2 and the NFkB pathways in cutaneous T-cell lymphoma.

Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis
This study of a large cohort of patients with indolent systemic mastocytosis demonstrates the incidence and clinical relevance (prognosis, phenotype) of KIT D816V as well as other somatic genetic mutations.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.